
- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Talaris Therapeutics
Talaris Therapeutics, Inc. operates as a biotechnology company. The Company focuses on developing proprietary method of allogeneic hematopoietic stem cell transplantation for chronic immunosuppression and treat patients who suffer from autoimmune diseases and non-malignant blood, immune, and metabolic disorders. Talaris Therapeutics serves patients in the United States.
Stock Analysis

last close
$2.3
1-mo return
-73.6%
3-mo return
-75.9%
avg daily vol.
285.12T
52-week high
17.48
52-week low
2.04
market cap.
$95M
forward pe
-
annual div.
-
roe
-64.6%
ltg forecast
-
dividend yield
-
annual rev.
$--
inst own.
79%